溶血磷脂酸
肺纤维化
受体
药理学
化学
医学
纤维化
生物化学
内科学
作者
Marta Giuliani,A. Rizzi,Mafalda Pagano,Luca F. Raveglia,Francesca Saccani,Maria Rosaria Di Lascia,Margherita Interlandi,Tonia Simona Nardella,Gessica Marchini,Annalisa Murgo,Laura Tigli,Alice Pappani,Anna Maria Capelli,Sara Gutiérrez Fernández,Paola Puccini,Gino Villetti,Maurizio Civelli,Claudia Beato,Elisa Moro,Claudia Mundi
标识
DOI:10.1021/acsmedchemlett.4c00559
摘要
Lysophosphatidic acid (LPA) is a phospholipid activating different biological functions by binding to G protein-coupled receptors (LPA1–6). Among these, the role of the LPA1 receptor in modulating fibrotic processes is well-known, making it a therapeutic target for pulmonary fibrosis and other fibrotic disorders. Herein we report the search for a new class of LPA1 antagonists for the oral treatment of idiopathic pulmonary fibrosis with a focus on hepatobiliary safety. Compound 7 excelled in in vitro and in vivo efficacy, showing significant efficacy both in PD studies and in a rodent lung fibrosis model, with a promising in vitro hepatic safety profile. However, in a dose range finding (DRF) toxicity study, compound 7 did not ensure safety regarding potential hepatobiliary toxicity, leading to its development being halted.
科研通智能强力驱动
Strongly Powered by AbleSci AI